Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 2/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229604 | 0.84 | SPR (0.47) | NPC1RAB9ACHRM4ALDH1A1HSD17B10 | |
| SCHEMBL4854577 | 0.80 | GSK3B (0.49) | NPC1LMNARAB9ACHRM4GSK3B | |
| SCHEMBL5231389 | 0.76 | SORT1 (0.40) | GSK3BKDM4EHPGDHSD17B10 | |
| SCHEMBL4848960 | 0.72 | GSK3B (0.49) | NPC1LMNARAB9AGSK3BKDM4E | |
| SCHEMBL4854304 | 0.71 | GSK3B (0.58) | LMNAGSK3BALDH1A1HPGD | |
| SCHEMBL5232508 | 0.66 | MAPK8 (0.55) | GSK3BWNT1DYRK1AMAPK8 | |
| SCHEMBL13986942 | 0.65 | GSK3B (0.48) | GSK3BWNT1DYRK1AKDM4EALDH1A1 | |
| SCHEMBL2077669 | 0.65 | NPC1 (0.60) | NPC1LMNARAB9ACHRM4PYGL | |
| SCHEMBL5236116 | 0.65 | GSK3B (0.52) | LMNAGSK3BDYRK1AALDH1A1MAPK8 | |
| SCHEMBL5233639 | 0.65 | GSK3B (0.52) | LMNAGSK3BWNT1DYRK1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | NPC1 1062/4885LMNA 680/4885RAB9A 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.